Fabry Disease – Epidemiology – Epidemiology Data Slicer

launch Related Market Assessment Reports

• Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

  May 2023

  Immune checkpoint inhibitors continue to dominate the treatment of non-small cell lung cancer (NSCLC), and biomarker-based approaches are increasingly segmenting the space and providing new…

• Osteoporosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  May 2023

  A wide array of drugs is available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…

• Non-Small-Cell Lung Cancer – Geographic Focus: China – Non-Small-Cell Lung Cancer – China In-Depth (China)

  April 2023

  Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…

• Psoriasis – Current Treatment – Detailed, Expanded Analysis Adult Psoriasis – Treatment Algorithms – Claims Data Analysis (US)

  April 2023

  Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not…

• Crohn’s Disease – Unmet Need – Detailed, Expanded Analysis (US & EU)

  TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’…